CLPBF (Coloplast AS) Retained Earnings : $2,319 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Coloplast AS Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Coloplast AS's retained earnings for the quarter that ended in Dec. 2024 was $2,319 Mil.

Coloplast AS's quarterly retained earnings declined from Jun. 2024 ($2,541 Mil) to Sep. 2024 ($2,291 Mil) but then increased from Sep. 2024 ($2,291 Mil) to Dec. 2024 ($2,319 Mil).

Coloplast AS's annual retained earnings increased from Sep. 2022 ($717 Mil) to Sep. 2023 ($2,094 Mil) and increased from Sep. 2023 ($2,094 Mil) to Sep. 2024 ($2,291 Mil).

Coloplast AS Retained Earnings Historical Data

The historical data trend for Coloplast AS's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS Retained Earnings Chart

Coloplast AS Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Retained Earnings

Get a 7-Day Free Trial

750.61

855.30

716.51

2,093.97

2,291.01

Coloplast AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															2,331.45	2,379.66	2,541.25	2,291.01	2,319.26

Coloplast AS Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Coloplast AS (OTCPK:CLPBF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Coloplast AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (OTCPK:CLPBF) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

CLPBY:USA COLOBc:UK 0QBO:UK COLO B:Denmark CBHD:Germany COLO:Austria

Address

Holtedam 1-3, Humlebaek, DNK, DK-3050

Website

https://www.coloplast.com

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.